With direct letters, regulatory comments and other activities, Vizient strives to form constructive relationships with lawmakers, regulatory agencies and administration officials, to provide a unified voice on issues that have a direct impact on our members.
2020 Advocacy
July 7 – Vizient submits policy requests to Congress on expansion of telehealth flexibilities
Vizient, Inc.
July 7 – Vizient comments to CMS on Policy and Regulatory Revisions in Response to the COVID-19 Public Health EmergencyVizient, Inc.
June 26 – Vizient comments to the USPTO regarding Patent Trial and Appeal Board Rules of Practice for Instituting on All Challenged Patent Claims and All Grounds and Eliminating the Presumption at Institution Favoring Petitioner as to Testimonial EvidenceVizient, Inc.
June 22 – Vizient submits comments to the Department of the Treasury and Federal Reserve Board on Main Street Lending Program Nonprofit LoansVizient, Inc.
May 11 – Vizient submits comments to DEA on Aggregate Production Quota Adjustments in Response to the Coronavirus Disease 2019 Public Health EmergencyVizient, Inc.
May 7 - Vizient joins hospital provider groups in urging support for liability protections for front-line providersVizient, Inc.
April 24 – Vizient submits comments to CMS on the Comprehensive Care for Joint Replacement ModelVizient, Inc.
April 23 - Vizient endorsed joint hospital letter to HHS/CMS re: Accelerated and Advanced PaymentsVizient, Inc.
April 16 - Vizient submits policy requests to Congress on COVID-19 reliefVizient, Inc.
March 23 – Vizient recommendations to the White House Coronavirus Task Force and FDA on Access to Chloroquine and HydroxychloroquineVizient, Inc.
March 16 – Vizient recommendations to the White House Coronavirus Task Force and CMS on Supply Strategies for Personal Protective Equipment and PharmaceuticalsVizient, Inc.
March 12 – Vizient endorsed coalition letter in support of funding for Children’s Hospitals Graduate Medical Education (CHGME) for FY 2021.Vizient, Inc.
March 6 – Vizient comments on Importation of Prescription DrugsVizient, Inc.
March 6 – Vizient comments to CMS on the Hospital Survey for Specified Covered Outpatient DrugsVizient, Inc.
January 31 – Vizient Comments to CMS on Medicaid Fiscal Accountability RegulationVizient, Inc.
January 27 – Vizient Comments to FDA on Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin ProductsVizient, Inc.
2019 Advocacy
Nov. 29 – Vizient’s response to the House Ways and Means Committee’s Rural and Underserved Health Care Task Force RFI
Vizient, Inc.
November 29 – Vizient comments on Hospital Survey for Specified Covered Outpatient DrugsVizient, Inc.
November 21 - Vizient Supports Opioid Workforce Act of 2019Vizient, Inc.
October 15 – Vizient comments on the DEA Proposed Aggregate Production Quotas for Schedule I and II Controlled SubstancesVizient, Inc.
September 27 - Vizient comments on the CY 2020 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed ruleVizient, Inc.
September 27 - Vizient comments on the CY 2020 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) proposed ruleVizient, Inc.
June 24 - Vizient comments on the FY 2020 Inpatient Prospective Payment System proposed ruleVizient, Inc.
May 31 - Vizient comments to CMS on promoting interoperability and increasing access to electronic health informationVizient, Inc.
May 30 - Vizient letter of support for the Protecting Local Access to Care for Everyone (PLACE) ActVizient, Inc.
May 10 - Vizient letter of support for the Affordable Prescriptions for Patients ActVizient, Inc.
May 7 - Vizient comments to FDA on the nonproprietary naming of biological productsVizient, Inc.
April 10 - Vizient endorsed coalition letter to members of Congress urging their support for the Resident Physician Shortage Reduction ActVizient, Inc.
March 29 - Vizient comments to CMS on potential updates to the Hospital Star Ratings methodologyVizient, Inc.
March 18 - Vizient comments to the FDA on updated draft guidance regarding the content of premarket submissions for management of cybersecurity in medical devicesVizient, Inc.
March 14 - Vizient letter of support for the FAST Generics Act of 2019Vizient, Inc.
March 14 - Vizient letter of support for the Biologic Patent Transparency ActVizient, Inc.
Feb. 19 - Vizient endorsed hospital coalition letter to Congress urging a delay in pending Medicaid DSH payment cutsVizient, Inc.
Feb. 15 - Vizient letter to the Senate cosponsors in support of the ACE Kids ActVizient, Inc.
Feb. 15 - Vizient letter to the House cosponsors in support of the ACE Kids ActVizient, Inc.
Feb. 8 - Vizient letter of support for the Resident Physician Shortage Reduction Act of 2019Vizient, Inc.
Feb. 5 - Vizient letter of support for the CREATES ActVizient, Inc.
Feb. 5 - Vizient endorsed coalition letter to the Senate in support of the CREATES Act.Vizient, Inc.
2018 Advocacy
Dec. 21 - Vizient comments to CMS on the International Pricing Index Model advanced notice of proposed rulemaking
Vizient, Inc.
Nov. 19 – Vizient-endorsed coalition letter to the Senate in support of the Overdose Prevention and Patient Safety ActVizient, Inc.
Nov. 19 - Vizient comments to CMS on the proposed rule to revise certain Medicare conditions of participation for providers and conditions for coverageVizient, Inc.
Sept. 24 – Vizient response to CMS request for information regarding a Competitive Acquisition Program for Medicare Part B drugs and biologics.Vizient, Inc.
Sept. 24 – Vizient comments on the FY 2019 outpatient prospective payment system proposed rule.Vizient, Inc.
Sept. 21 - Vizient comments to the FDA on facilitating competition and innovation in the biological products marketplaceVizient, Inc.
Sept. 19 - Vizient-endorsed coalition letter supporting inclusion of coordinated care provisions in final opioid agreementVizient, Inc.
Sept. 19 - Vizient Comments to DEA on Proposed Controlled Substance Quotas for 2019Vizient, Inc.
Sept. 10 - Vizient comments on the CY 2019 Physician Fee Schedule and Quality Payment Program proposed ruleVizient, Inc.
Aug. 31 - Vizient comments to CMS on the CY 2019 Home Health proposed ruleVizient, Inc.
August 23 - Vizient-endorsed coalition letter urging the FDA to finalize guidance critical to lower drug pricesVizient, Inc.
July 16 - Vizient comments on HHS request for information on ways to lower drug prices and reduce out-of-pocket costs for consumersVizient Inc.
June 12 - Vizient letter of support for the SERV Communities Act.Vizient, Inc.
June 25 - Vizient comments on the FY 2019 Inpatient Prospective Payment System proposed ruleVizient, Inc.
June 7 - Vizient-endorsed coalition letter to the Senate Judiciary Committee in support of the CREATES Act.Vizient, Inc.
May 30, 2018 - Vizient feedback on the CMS methodology for the Overall Hospital Quality Star RatingVizient Inc.
May 30 - Vizient comments to the FDA regarding its Medical Device Safety Action Plan.Vizient, Inc.
May 22 - Vizient comments to the IRS in support of further agency guidance around hospital community benefit.Vizient, Inc.
May 15 - Vizient-endorsed hospital letter to House Energy and Commerce Committee in support of modifying the IMD exclusion.Vizient, Inc.
May 11 – Vizient comment letter to USTR on proposed policies and tariffs against Chinese productsVizient, Inc.
May 3 - Vizient Comments to DEA on Controlled Substance QuotasVizient, Inc.
March 29 - Vizient letter to USP providing feedback on biosimilar namingVizient, Inc.
March 26 - Vizient letter of support for H.R. 5385, the Children's Hospital GME Support Reauthorization Act.Vizient, Inc.
March 26 - Vizient letter of support for S. 2597, the Children's Hospital GME Support Reauthorization Act.Vizient, Inc.
Feb. 6 - Vizient endorsed coalition letter urging passage of the CREATES Act.Vizient, Inc.
Jan. 17 - Vizient endorsed hospital coalition letter to the House supporting delay of Medicaid DSH cuts and extension of Medicare Dependent Hospital and Low Volume Adjustment programs in continuing resolution.Vizient, Inc.
Jan. 17 - Vizient endorsed hospital coalition letter to the Senate supporting delay of Medicaid DSH cuts and extension of Medicare Dependent Hospital and Low Volume Adjustment programs in continuing resolution.Vizient
2017 Advocacy
Nov. 20 - Vizient comment letter in response to request for information on the new direction for CMMI.
Vizient, Inc.
Nov. 17 - Vizient endorsement of H.R. 4392 to prevent CMS from implementing payment reductions for 340B eligible hospitalsVizient, Inc.
Oct. 16 - Vizient comment letter to CMS on proposed cancellation of Episode Payment Models and changes CJR program.Vizient, Inc.
Oct. 13 - Vizient-endorsed coalition letter seeking congressional action on home infusion wraparound paymentsVizient, Inc.
Sept. 27 - Vizient comments to CMS on proposed changes to the Hospital Star Ratings methodology.Vizient, Inc.
Sept. 19 - Vizient-endorsed coalition letter to the House in support of the CREATES Act.Vizient, Inc.
Sept. 19 - Vizient endorsed coalition letter to the Senate in support of the CREATES Act.Vizient, Inc.
Sept. 18 - Vizient-endorsed hospital letter to the House urging a delay in pending Mediciad DSH payment cuts.Vizient, Inc.
Sept. 18 - Vizient-endorsed hospital coalition letter to the Senate urging a delay in pending Medicaid DSH cutsVizient, Inc.
Sept. 11 - Vizient comment letter to CMS on the Outpatient Prospective Payment System proposed ruleVizient, Inc.
Sept. 11 - Vizient comment letter to CMS on the proposed 2018 physician fee schedule.Vizient, Inc.
Sept. 5 - Vizient-endorsed coalition letter in support of extending the Children's Health Insurance Program and other safety-net programs.Vizient, Inc.
August 28 - Vizient comment letter to CMS on proposed DSH allotment reductionsVizient Inc.
Aug. 21 - Vizient Comments to CMS on Year 2 of the Quality Payment ProgramChelsea Arnone, Shoshana Krilow
August 3 - Vizient comment letter to the IRS and Treasury Department calling for additional guidance for tax exempt hospitals related to social-determinants of health and accountable care organizations.Vizient Inc.
July 26 - Vizient letter of endorsement for H.R. 3325, the ACE Kids ActVizient Inc.
June 13 - Vizient comments on the FY2018 Inpatient Prospective Payment System proposed ruleVizient Inc.
May 23 – Vizient’s comments on ACA repeal and replace efforts to Senate Finance Committee Chairman Orrin Hatch (R-Utah)Vizient, Inc.
May 19 – Vizient’s comments to the Food and Drug Administration regarding biosimilar Demonstration Interchangeability with a Reference ProductVizient, Inc.
May 18 – Vizient statement for the record for House Ways and Means Health Subcommittee hearing on the Medicare programVizient, Inc.
May 16 – Vizient letter of endorsement for H.R. 2267, The Resident Physician Shortage Reduction ActVizient, Inc.
May 5 - Vizient statement on the House passage of the American Health Care Act
April 19 – Vizient comment letter to CMS on Episode Payment Model Interim Final RuleVizient, Inc.
April 17 – Vizient letter of endorsement for the FAST Generics ActVizient, Inc.
April 14 – Vizient letter to Sen. Michael Bennet (D-CO) in support of the ACE Kids ActVizient, Inc.
April 14 – Vizient letter to Sen. Charles Grassley (R-Iowa) in support of the ACE Kids ActVizient, Inc.
Jan. 18 – Vizient letter to President-elect Trump detailing positioning on efforts to repeal and replace the ACAVizient, Inc.
Jan. 18 – Vizient letter to HHS Secretary Appointee Dr. Tom Price detailing positioning on efforts to repeal and replace the ACAVizient, Inc.
Jan. 18 – Vizient letter to House and Senate leadership detailing positioning on efforts to repeal and replace the ACAVizient, Inc.
Connect with Vizient to help you solve health care’s biggest challenges